Previous 10 | Next 10 |
MIRAMAR, Fla., April 14, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) today announced that the company is working with corporate collaborators, academic advisors, and contract manufacturers, wi...
MIRAMAR, Fla., April 06, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) President & CEO Joseph Moscato offers an open letter to shareholders to provide an update on the company’s response,...
The BPA contract facilitates the sales and distribution of Excellagen across the VA system’s 165 hospitals Excellagen wound conforming matrix is used to manage wounds including Diabetic Foot Ulcers, that affect a staggering 21% of our veterans MIRAMAR, Fla., March 30, 2020 (GLO...
MIRAMAR, Fla., March 30, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) announced that today Dr. Eric von Hofe, PhD, Chief Scientific Officer of NuGenerex Immuno-Oncology (NGIO), a Generex ...
Generex’s Ii-Key peptide vaccines for infectious disease and cancer have been studied in human clinical trials involving over 300 subjects in Phase I and Phase II clinical trials See publications at https://generex.com/covid-19 A Phase I clinical trial demonstrating the safe...
NuGenerex Immuno-Oncology (NGIO) is focused on modulation of the immune system to develop Ii-Key peptide vaccines for the treatment and prevention of cancer and infectious diseases NGIO advancing Ii-Key peptide vaccines into development with partners in the United States and China in an e...
MIRAMAR, Fla., March 11, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT), and its subsidiary, NuGenerex Immune-Oncology (NGIO), have been featured in several news outlets and on a podcast regarding its Ii-Key vaccine platform and its development of a COVID-19 (corona...
It is an exciting time in biotech. It seems like the big challenges are within reach. Cancer, diabetes, infectious diseases. Not everything, not right away. There are still a lot of bald men, for example. And unfortunately, Alzheimer’s seems intractable. But for investors that can mea...
2020 Komen More Than Pink™ Walk Saturday March 14, 2020 in Orlando, Florida MIRAMAR, Fla., March 10, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that NuGenerex Immuno-Oncology is sponsoring the Susan G. Komen More than Pink Walk...
-- Terms approved to proceed with collaborative effort with international consortium MIRAMAR, Fla., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) today announced that the company has...
News, Short Squeeze, Breakout and More Instantly...
Generex Biotechnology Company Name:
GNBT Stock Symbol:
OTCMKTS Market:
Generex Biotechnology Website:
MIRAMAR, Fla., July 26, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) subsidiary Olaregen Therapeutix announced in May that the company has executed a Distribution Agreement with Nexgen Medical Sdn Bhd, Inc. (“Nexgen”) to be Ge...
Ii-Key Immunotherapeutic Vaccine Technology Ii-Key-SARS-CoV-2 Vaccine Market Potential & International Contracts Market Potential for AE37 (Ii-Key-HER2) Immunotherapeutic Vaccine for breast, prostate, and bladder cancers MIRAMAR, Fla., June 22, 2021 (GLOBE NEWSWIRE) --...
NuGenHealth Software as a Service (SaaS) platform that enables their clients to monitor the health and wellbeing of their patient population. Westside Medicine & Cardiology, Inc. is a professional corporation that engages medical providers who are duly licensed in Ohio ...